ما هو العلاج الخط الأول لداء الراصات الباردة؟

References

• Current clinical practice guidelines currently recommend rituximab with or without bendamustine as first-line therapy for CAD.
• Can be used first-line in symptomatic CAD.
• According to the British Society of Haematology: "Patients should be advised to avoid cold exposure where possible (1C)."
• According to the British Society of Haematology: "Patients with AIHA should receive folic acid supplementation (1B)."
• British Society of Haematology: "Thromboprophylaxis with low molecular weight heparin is recommended for in-patients with an acute exacerbation of haemolysis (1C) and should be considered in ambulatory patients during severe exacerbations (Hb<85 g/l) (2C)."
• Increase in Hb levels in patients with symptom-producing anemia including achievement of transfusion independency.
• Improvement or resolution of disabling cold-induced circulatory symptoms.
• Time to response in CAD ranges from 1 to 8 months.